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Abstract
Post-translational modifications controlling a large number of biological functions are key aspects of protein diversity. 
They have an important role controlling cellular processes and may be advantageously utilized. Qualitative and quantitative 
analyses of post-translational modifications are useful for biomarker research and an integral part of the characterization 
of protein biopharmaceuticals. Due to its sensitivity and widespread applicability, mass spectrometry has become the core 
technology of the analysis especially when combined with chromatographic and other separation techniques. The aim of this 
article is to present a general overview of mass spectrometry applications in the field of PTM mapping. We also present the 
analytical challenges of particular PTMs, primarily focusing on the most frequent modifications.
Keywords Protein · Post-translational modification · Mass spectrometry · Liquid chromatography
Introduction
One of the main goals of molecular biology is to under-
stand the working mechanism of cells or even the whole 
organism. In this context, an essential step is to identify 
and characterize processes present in cells at the molecu-
lar level. An important milestone was the Human Genome 
Project, in which the sequence of 3 billion nucleotide base 
pairs that build up human DNA pool were identified, and 
all the genes have been mapped [1]. The genome is almost 
identical in every human cell and is nearly constant during 
the lifespan of an organism. In contrast, the proteins in a cell 
are much more numerous, vary significantly both among 
various cells and during the lifetime of a cell [2]. While 
the genome contains between 20,000 and 25,000 genes, the 
transcriptome consists of approximately 100,000 transcripts 
and the proteome exceeds 1 million proteins (Fig. 1) [3]. 
The expansion from the genome to the proteome is based on 
two major mechanisms during transcription and protein syn-
thesis. Most eukaryotic genes contain multiple non-coding 
intron sequences, which are copied into the precursor mes-
senger RNA (pre-mRNA). During the mechanism of splic-
ing, these sequences are removed from the pre-mRNA and 
exons are joined together, forming the mature mRNA. Exons 
can be ligated together in multiple ways, providing different 
mRNAs and protein isoforms. This phenomenon—so-called 
alternative splicing—is one of the key generators of protein 
diversity [4]. The second way to increase complexity is the 
covalent and commonly enzymatic alteration of the folded 
or the nascent protein during or after protein biosynthesis. 
These so-called post-translational modifications have two 
major categories: covalent addition of a functional group 
and cleavage of the peptide bond in the process of convert-
ing a propeptide to the mature form. However, in a broader 
context, non-enzymatic addition of a modifying group, 
autocatalytic cleavages and other structural changes (e.g. 
formation of disulfide bridges, cyclisation of asparagine or 
aspartic acid residues, racemization, etc.) can be considered 
as post-translational modifications as well [5].
A vast number of chemical groups can attach as PTM to 
different parts of the peptides and proteins, greatly increas-
ing the chemical repertoire of the 20 standard amino acids. 
The addition of modifying groups may take place on elec-
tron-rich functional groups that act as a nucleophile in the 
process, such as hydroxy groups of tyrosine, threonine, 
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serine, amino groups of arginine and lysine, carboxyl group 
of glutamate and aspartate or at the C or N termini of the 
protein [6]. Table 1 lists the most frequent types of PTMs.
The biological function of over 200 PTMs have been 
reported, including cellular localization, turnover and activ-
ity state of proteins, modulation of gene expression, acti-
vation of enzymes, interactions, etc. [6]. Nevertheless, the 
physiological relevance of many PTMs is still unknown, or 
only partially understood. The significance of post-transla-
tional modifications goes far beyond their role in cellular, 
physiological processes. A vast number of analytical data 
indicate that in various physiological and/or pathological 
states (pregnancy, inflammation, cancer) the structure, sugar 
composition, and the absolute and relative amount of various 
glycoforms change significantly, and often anomal molecule 
variants can also be detected. It seems that various patho-
physiological processes are reflected by the qualitative and 
quantitative fingerprints of the antennary oligosaccharide 
structure of glycoproteins [12–19]. A number of ongoing 
research projects pay particular attention to the altered gly-
cosylation and diagnostic value of circulating glycoproteins 
and use them as promising biomarkers. Altered phosphoryla-
tion and acetylation are also associated with some diseases 
[20, 21].
The biopharmaceutical industry has been growing con-
stantly over the past few decades. Today, hundreds of thera-
peutic proteins are in medical use, the majority of which—
according to the type of expression system—bear simple 
or complex PTMs, highlighting the importance of such 
structural features. Their significance lies in their ability to 
influence functional activity, stability, and immunogenicity 
of the product. Detailed characterization of PTMs is, there-
fore, indispensable during the development of both original 
biopharmaceutical products and biosimilars [22].
Fig. 1  The increase in complex-
ity from the genome to the 
proteome
Table 1  Most frequent post-translational modifications, their localization, and functions [8–11]
a Frequency refers to the relative abundances of each PTM found putatively and experimentally in Swiss-Prot database [7]
PTM type Frequencya Localization Main functions
Phosphorylation 58,383 Serine, threonine Regulation of enzyme activity
Acetylation 6751 Lysine, N terminus Subcellular localization, protein stability, 
regulation of DNA–protein interactions
O/N-linked glycosylation 6659 Serine, threonine/asparagine Protein folding/stability, cellular adhesion
Amidation 2844 C terminus Signal transduction, receptor recognition
Hydroxylation 1619 Proline, lysine Stability of collagen
Methylation 1523 Lysine, arginine Regulation of protein–protein interactions
Ubiquitination 878 Lysine, cysteine, serine, threonine, N 
terminus
Proteosomal degradation
Pyroglutamic acid 826 Glutamic acid, glutamine Protein stability
Sulfation 504 Tyrosine Strenghtening protein–protein interactions
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Despite the great significance of PTMs, their large-
scale investigation has been hindered for a long time by 
the absence of suitable analytical techniques. Mass spec-
trometry, especially coupled to high performance liquid 
chromatography, has often become the method of choice 
for qualitative and quantitative PTM analyses [23]. In the 
present article, we give an overview of the role of mass 
spectrometry for analysis of post-translational modifications, 
with particular emphasis on the most common ones, such as 
phosphorylation, acetylation, O/N glycosylation, amidation, 
and hydroxylation.
Principles and Trends in Mass 
Spectrometry‑Based PTM Mapping
Analysis of proteins requires soft ionization techniques, such 
as matrix-assisted laser desorption/ionization (MALDI) and 
electrospray ionization (ESI), that are able to ionize ther-
molabile and non-volatile compounds without considerable 
fragmentation [24]. In MALDI, samples are co-crystallized 
with a large amount of UV-absorbing matrix material on a 
metal plate and are bombarded by a pulsed UV laser, gen-
erating volatilized and typically +1 charged particles [25]. 
However, novel matrices support the formation of multiply 
charged ions providing improved fragmentation efficiency 
and enabling the use of electron-based fragmentation meth-
ods, which can be highly beneficial in the analysis of labile 
PTMs (see later in the section) [26]. This ionization tech-
nique allows direct analysis of mixtures and biomolecules 
in a wide molecular mass range (~ 300–200,000 Da). Addi-
tionally, it is considerably tolerant of salt contamination 
[25]. The most important disadvantage of MALDI is that 
it is not straightforward to couple it to liquid chromatog-
raphy on-line. Furthermore, quantitation using MALDI is 
often considered inaccurate. In ESI, a liquid sample solu-
tion passes through an electrically charged capillary to the 
ion source, where a nebulizer gas helps ionization. As there 
is a few kV potential difference between the electrospray 
tip (capillary) and the entrance of the mass spectrometer, 
and the liquid leaving the capillary forms charged liquid 
droplets [27], multiply charged (protonated or cationized) 
ions are generated from these droplets. This makes ESI well 
suited for analysis of both small and large molecules, such 
as peptides, proteins, glycoproteins, oligonucleotides. Elec-
trospray has better reproducibility than MALDI and is far 
better suited for quantitation. Direct coupling of ESI with 
separation techniques (such as HPLC or CE) is typical, and 
quite straightforward.
Structure analysis by mass spectrometry, and especially 
by tandem mass spectrometry, is based on fragmentation 
(the nascent molecular ion producing fragment ions by spe-
cific chemical reactions). Excitation of the ion to be studied 
(often, but not always the molecular ion) is accomplished by 
a variety of methods, most typically collision-induced dis-
sociation (CID) is used (sometimes, also called collisionally 
activated dissociation, CAD). In this process, the precursor 
ion (accelerated in the mass spectrometer) collides with a 
neutral gas in the collision chamber. In the case of peptides 
and proteins, this results in a cleavage of the peptide back-
bone, yielding mostly b- and y-type fragments [28], which 
can be used to determine the peptide sequence. When the 
peptide bears labile modifications (e.g. phosphorylation, 
sulfonation), the predominant cleavage site may be redi-
rected, often leading to loss of the labile modification. As 
a consequence, the spectra may be inadequate to determine 
the peptide sequence and/or the localization of modification.
Electron capture dissociation (ECD) is an alternative of 
CID. In ECD, the precursor ion (e.g. a multiply protonated 
peptide) captures one (or more) low-energy electrons, and 
then quickly dissociates. ECD generates cleavage at N–Cα 
bond of the peptide backbone, providing c- and z-type frag-
ment ions. Probably, the most engaging characteristic of this 
fragmentation method is that labile PTMs generally remain 
intact. An alternative of ECD is electron transfer dissocia-
tion (ETD) [29], showing similar fragmentation.
Detailed characterization of the PTM of a protein (or set 
for proteins) is a challenging task. First of all, these modi-
fications are generally heterogeneous, thus the amount of a 
given PTM variant (isoform or glycoform) is only a frac-
tion of the total protein amount. Second, the dynamic range 
of human proteome (i.e. the concentration of abundant or 
minor proteins/isoforms) exceeds several orders of magni-
tude, aggravating identification and quantification of low-
abundance proteins or isoforms. Third, full structural char-
acterization of a protein requires much more substance and 
analysis time than a “simple” identification based on a few 
peptide fragments [23]. Fourth, biological samples are often 
available in limited amounts only, such as tumor biopsies or 
tissue slices [30]. These complications highlight the impor-
tance using elaborate sample pretreatment, separation and 
enrichment methods for protein analysis. A large number of 
strategies have been developed to recover sufficient amount 
of proteins even if the amount of biological material is very 
small (< 100 μg) [30]. Although development and imple-
mentation of such techniques is time-consuming, they are 
indispensable to decrease the complexity of the biological 
sample prior to MS analysis.
The commonly used methods can be divided into gel-
based and gel-free approaches [31]. Generally, the former 
works better at the protein level, the latter at the peptide 
level. Gel-based techniques usually employ sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) or 
two-dimensional gel electrophoresis (2-DE), in which the 
first dimension refers to separation based on the pI, then 
the analytes are separated according to their molecular 
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weight in the second dimension. Various procedures, for 
instance, immobilized pH gradient, can improve sensitiv-
ity and selectivity to get a more exhaustive picture of the 
analytes. Despite its favorable efficiency, the method has 
a number of limitations, such as slowness and incapability 
for high throughput analysis. The use of gel electrophoresis 
is further aggravated by high dynamic range of proteins in 
biological samples. Gel-based techniques are often followed 
by MALDI analysis. In such case, the protein line or spot is 
cut out, digested in the gel and sampled by MALDI [32], or 
(in more complex cases) may be analyzed by (nano)LC–MS/
MS [30]. Gel-free techniques include a variety of liquid 
chromatographic techniques and capillary electrophoresis 
(CE) [33]. Amongst several multidimensional LC methods, 
the most commonly applied technique separates the peptide 
mixture using strong cation-exchange (SCX) chromatogra-
phy, followed by RP-LC–MS/MS. The principle behind this 
is that peptides are first separated based on their charge, 
and in the sequel based on their hydrophobicity. SCX chro-
matography can be coupled on-line as well as off-line to 
RP-HPLC [33].
Mass spectrometric approaches for PTM analysis and for 
“conventional” protein identification are analogous, and may 
be considered bottom-up, middle-down, and top-down prot-
eomics [34]. In the bottom-up approach, peptides (typically 
in the 500–3000 mass range), produced by the enzymatic 
digestion of proteins, are studied. When this is performed 
on a large set of proteins, such as plasma or cell lysate, this 
is often called “shotgun proteomics” [35]. This approach is 
the most widespread and popular, owing to its sensitivity and 
high throughput [36]. As it has mentioned above, bottom-
up approach works at the peptide level. A serine protease, 
trypsin is generally employed for this purpose, which cleaves 
the peptide bonds at the carboxyl side of basic amino acids, 
such as arginine and lysine generating oligopeptides in the 
optimal mass range for chromatographic separation, and the 
emerging peptides can be ionized properly in ESI due to 
their basic amino acid content, yielding satisfactory infor-
mation to determine the parent protein. On the other hand, 
this strategy has serious limitations, which make bottom-up 
approach suboptimal for PTM mapping and identification 
of alternatively spliced protein variants. The main reason 
is that only a fraction of the peptide fragments is usually 
observed in MS analysis, resulting in a sequence typically 
in 20–60% range (and there will be no information of the 
rest of the protein). Tryptic digestion may also result in very 
short peptides, that are inappropriate for LC–MS analysis, 
and even if observed, do not contain much information. This 
is often a problem for analyzing Arg- and Lys-rich proteins, 
such as histones [37].
In the case of top-down proteomics, intact proteins are 
directly introduced and fragmented in a tandem mass spec-
trometer, without being subjected to proteolytic digestion. 
Middle-down proteomics is an in-between case, which can 
be considered as a mixture of top-down and bottom-up 
methods. This procedure works with 5–20 kDa large poly-
peptides, produced by limited proteolytic digestion [34]. Fig-
ure 2 presents workflows with respect to these proteomic 
strategies.
Working at the protein level (i.e. with the top-down 
approach) offers a number of advantages in the field of 
PTM mapping. Since the whole protein is studied, there is 
no complication due to the different ionization efficiencies of 
peptide fragments. The top-down approach is able to identify 
sequence variants and PTM combinations as well [38]. It is 
particularly useful for the characterization of small proteins 
[38]. On the other hand, top-down proteomics is generally 
restricted to individual proteins or simple mixtures [39]; has 
relatively low sensitivity and data evaluation is very time-
consuming; therefore, it is unsuitable for high-throughput 
work [40].
Mass Spectrometric Analysis of the Most 
Frequent Post‑translational Modifications
Phosphorylation
Phosphorylation is widespread and often studied protein 
modification. Serine, threonine, and tyrosine residues are 
covalently modified by the enzymatic addition of a phos-
phate group. Phosphorylation is a reversible process, typi-
cally used to switch on and off various biological processes. 
The presence of the charged, hydrophilic group changes the 
structure of proteins, regulating multiple biochemical pro-
cesses, for instance, cell cycle, metabolism and regulation 
of receptors [41, 42].
Phosphorylation of a given site typically occurs only in 
a (small) fraction of molecules. Phosphorylation analysis, 
therefore, requires both structure assignment (identification 
of the phosphorylation site) and determining the propor-
tion of phosphorylated and non-phosphorylated analogs. 
Phosphoproteins constitute only a small fraction of the pro-
teome, consequently enrichment strategies are essential for 
successful analysis. Several methods have been developed 
for this purpose, such as immunoaffinity chromatography, 
immobilized metal ion affinity chromatography (IMAC), 
and metal oxide affinity chromatography (MOAC) such as 
titanium dioxide  (TiO2) and zirconium dioxide  (ZrO2) chro-
matography [43–46]. IMAC and MOAC are based on the 
affinity of the phosphate groups for transition metal ions 
and metal oxides. However, these materials also show affin-
ity for carboxyl groups, resulting in the isolation of acidic 
residues such as glutamate and aspartate-containing pep-
tides alongside phosphorylated ones [47, 48]. Numerous 
strategies have been developed to overcome these specificity 
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Fig. 2  Typical proteomic work-
flows [33]
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issues. Esterification of carboxyl groups prior to enrichment 
reduces the retention of acidic peptides. Organic acids hav-
ing higher affinity for the stationary phase than carboxyl 
groups but lower than phosphate groups are employed as 
non-phosphopeptide excluders. Phosphopeptides can also 
be specifically eluted from the IMAC material using beta 
elimination, which removes the bond between the peptide 
and the phosphate group [48]. Although MOAC is shown 
to be more resistant to interfering compounds (e.g. salts, 
detergents) and more selective than IMAC in many cases, 
multiply phosphorylated residues may bind with high affin-
ity to the metal oxide, which makes them dramatically dif-
ficult to elute. IMAC, therefore, provides improved coverage 
of multiphosphorylated peptides, and it is also able to enrich 
full-length phosphoproteins without any prior proteolytic 
digestion [48–50]. Immunoaffinity chromatography is pre-
dominantly employed in the enrichment of proteins phos-
phorylated on the tyrosine residue [51]. Considering that the 
data obtained with different enrichment methods only partly 
overlap each other (around 30%), combination of multiple 
methods is recommended to improve phosphoproteome cov-
erage [52]. The enriched samples can be subsequently frac-
tionated prior to MS analysis by multiple methods such as 
hydrophilic interaction chromatography (HILIC), RP-HPLC, 
and SCX [53–55].
There are two important issues that make phosphoryl-
ated peptide characterization by MS nontrivial. First, the 
sensitivity of a phosphopeptide is significantly lower than 
that of its non-phosphorylated analog [56]. Second, phos-
phopeptides typically fragment in CID by losing phosphoric 
acid, and therefore, identification of the phosphorylation site 
may be compromised [43]. Using ECD, ETD and/or spe-
cial MS/MS techniques (such as  MS3) may alleviate this 
problem and allow both sequence analysis and locating the 
phosphorylation site [57]. Phosphopeptide analysis may be 
performed using derivatization as well. Phosphoserine and 
phosphothreonine residues are selectively transformed into 
lysine analog; and subsequent proteolytic cleavage (using, 
e.g. trypsin or Lys-C) results in novel peptides [58]. Identi-
fying these peptides using MS/MS and comparing it to the 
MS/MS of non-derivatized analog can be used to identify 
the phosphorylation site [46, 58].
Acetylation
Over the last few years, study of protein acetylation has 
become a major issue in PTM analysis. Proteins can be acet-
ylated at the N terminus and at the ε-amino group of lysine 
residues, the latter having the greater biological relevance. 
Acetylation has been most extensively characterized for the 
regulation of histones, concluding that it plays an important 
role in cell cycle processes, such as gene expression and 
DNA repair [59, 60].
Since acetylation usually occurs at a very low stoichi-
ometry, enrichment of the modified proteins and peptides 
is of critical relevance. Acetyllysine-specific antibodies 
are highly valuable for this purpose, and used as the initial 
purification step of very complex samples [61–63]. How-
ever, the method works properly only for peptides, as the 
accessibility of acetylated amino-acid residues is limited in 
the case of intact proteins. Moreover, there is no available 
antibody for the enrichment of N-terminal acetylation [64]. 
A number of methods are accessible for the prefractionation 
of histones including size exclusion chromatography (SEC), 
SDS-PAGE, and CE [65–67]. Acetylation increases the 
hydrophobic character of proteins and removes the positive 
charge from the N-terminal amino group. Acetylated resi-
dues, therefore, can be separated from their non-acetylated 
counterparts based on hydrophobicity (RP-HPLC), electro-
static interactions (SCX), or both (zwitterionic hydrophilic 
interaction liquid chromatography, ZIC-HILIC) [64, 68]. 
HILIC also has the added value of being able to separate 
methylated and acetylated histones, significantly decreasing 
sample complexity [69]. Another possibility for reducing 
sample complexity is derivatization by propionic anhydride, 
which converts lysine residues and the N-terminal amino 
group into propionyl amides providing a + 56 Da mass shift 
and protection from enzymatic digestion [37, 70].
Lysine acetylation is considered to be a stable PTM under 
mass spectrometry analysis, i.e. the functional group is 
retained on the protein using high-energy CID [23]. Acety-
lation can be identified through a 42.01 Da mass shift, in 
contrast with the unmodified variant. Although another 
modification called trimethylated lysine has a very similar 
weight (42.04 Da) to lysine acetylation, high-resolution mass 
spectrometers are capable to differentiate such modifications 
[71]. Since acetylation neutralizes the positive charge of 
lysine residue and blocks the tryptic cleavage, the absence 
of this characteristic cleavage can be another sign of acety-
lation [72].
O/N Glycosylation
Approximately, more than the half of human proteins bears 
simple or complex glycan side-chains, influencing protein 
folding and stability [73, 74]. There are two major types 
of glycan side-chains: (1) O-linked glycans attached to 
the hydroxy group of serine, threonine, tyrosine, while, (2) 
N-linked glycans are attached to the nitrogen of asparagine 
side-chains. In contrast to the synthesis of nucleic acids and 
proteins, glycosylation processes are not template directed, 
providing great heterogeneity for glycoconjugates. Conse-
quently, a glycoprotein is a mixture of protein isoforms (gly-
coforms), instead of being a well-defined, exact chemical 
entity [75].
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Complete characterization of glycoproteins and glycopep-
tides requires multiple analytical methods. In one approach, 
glycan side-chains are released from the protein by the appli-
cation of an enzyme (e.g. peptide N-glycosidase F, PNGase 
F) or by reductive elimination. The former can be used in 
the case of N-glycans, and the latter for O-glycans [76–79]. 
When the sugars are released, they are typically separated 
from the protein mixture and derivatized. Replacing all reac-
tive hydrogens with methyl groups (permethylation) is the 
most widespread method for this purpose, which enables 
detailed structural determination of complex glycans (e.g. 
branching sites, interglycosidic linkages, configurational iso-
mers) [82]. As the procedure stabilizes sialic acid residues, 
permethylated derivatives show more effective ionization 
and more predictable fragmentation properties compared 
to their native counterparts [80–84]. Permethylated glycans 
are most often analyzed by MALDI-MS. Anthranilic acid 
(2-aminobenzoic acid, 2-AA) labeling of reducing carbohy-
drates is carried out in mild conditions, therefore, undesir-
able desialylation can be avoided [85]. 2-AA tag improves 
both chromatographic and mass spectrometric (in negative 
ion mode) detectabilities of glycans by acting as a chromo-
phore, fluorophore and adding a negative charge to all the 
molecules. It also provides more informative fragments 
facilitating sequential analysis of saccharides [81, 85–88]. 
The derivatives can be subsequently separated by a number 
of methods, such as HILIC and CE prior to mass spectromet-
ric analysis. CE is capable of separating positional isomers 
as well as differently linked glycans with high resolution 
and short analysis time, while HILIC tends to yield better 
retention time repeatability [89, 90]. It is also demonstrated 
that the techniques show notable complementarity in the 
glycoform profiling of therapeutic proteins [91].
An alternative to release glycan analysis is digestion of 
the protein (mixture) with proteolytic enzymes (e.g. trypsin). 
This yields a mixture of peptides and glycopeptides, and 
can be analyzed by CID- or ECD-based tandem mass spec-
trometry. Enzymatic digestion is often followed by enrich-
ment techniques prior to the MS analysis. Glycopeptides 
may be enriched by boronate affinity chromatography, lec-
tin affinity chromatography, HILIC, and electrostatic repul-
sion-hydrophilic interaction chromatography (ERLIC) [75, 
92–96]. Boronate affinity chromatography is able to capture 
glycan moieties through formation of borate diesters with 
vicinal diols of the sugar residues. This ensures selective 
enrichment of glycopeptides, even in complex mixtures. In 
contrast to boronate affinity chromatography, lectin affin-
ity chromatography allows the enrichment of unique gly-
coproteins/peptides having specific glycan structure, which 
may be exceptionally useful in the exploration of disease-
related, abnormal glycosylation pattern [97]. As glycosyla-
tion increases hydrophilicity of proteins and peptides, glyco-
peptides can be easily separated from non-glycosylated ones 
by HILIC. ERLIC, in which positively charged functional 
groups are attached to the stationary phase, can be consid-
ered as a combination of hydrophilic interaction and ion-
exchange chromatography. Sialylated moieties with nega-
tive charge are, therefore, highly retained, while positively 
charged peptides are easily eluted [98]. It is also reported 
that certain gradient HILIC methods can be converted into 
isocratic separations by ERLIC [99].
There are various mass spectrometric approaches for 
glycopeptide analysis, identifying the glycan structure, the 
glycosylation site and also the abundance ratio of various 
glycoforms. CID fragmentation often cleaves off the sugar 
residue, while ECD and ETD can yield information on the 
peptide sequence [75]. Ion mobility–mass spectrometry (IM-
MS) is also a promising analytical tool in this field with the 
added value of being able to separate analytes based on their 
size. This technique has been successfully applied for the 
separation and characterization of isobaric polysaccharides 
and glycopeptides [100, 101].
Amidation
Approximately, half of the endocrine and neural peptides 
bear C-terminal amidation [102]. The presence of such 
modification is indispensable for signal transduction and 
receptor recognition [102, 103]. Furthermore, derivatization 
of amidated peptides with glycosylphosphatidylinositol is 
responsible for anchoring peptides and proteins to the cell 
membrane [104].
As in most cases in the field of PTMs, proteins that are 
presumably amidated at the C terminus can be separated 
or enriched by specifically engineered approaches based on 
the affinity of such proteins. For a long time, only radioim-
munoassay (RIA) and immunoprecipitation (IP) have been 
applied for identification of amidated proteins [105, 106]. 
Separation of amidated peptides from their precursors can 
be carried out with RP-HPLC [105]. Weak cation-exchange 
chromatography (WCX) has been reported to be able to 
separate the α-amidated heavy chain of immunoglobulin 
G1 from other isoforms [107].
Amidation of a carboxyl group manifests in a 1 Da mass 
shift, which is very difficult to identify. The situation can 
be further complicated when the C-terminal amino acid is 
glutamine or asparagine, which cannot be distinguished from 
the amidated form of glutamate or aspartate, except when 
an auxiliary chemical or enzymatic procedure is performed. 
An approach has been developed for detecting C-terminal 
amidation by a combination of chemical derivatization and 
MALDI-TOF/TOF MS [86]. First step is the derivatization 
of the free carboxyl group at the C terminal, resulting in a 
methylamide structure [108, 109]. This results in a 13 Da 
mass increment observable in the spectrum, enabling the dis-
tinction between the amidated and the unmodified peptides. 
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This method was shown to be able to distinguish isobaric 
residues at the C terminal, such as Gln-OH and Glu-NH2 
or Asn-OH and Asp-NH2, suggesting a wider application to 
investigate modified and unmodified C terminals of proteins 
[104].
Hydroxylation
Although hydroxylation can take place on several amino 
acids including lysine, histidine, asparagine, aspartate, and 
aromatic residues, the most commonly hydroxylated amino 
acid is proline, which makes up almost one-third of collagen 
protein [110–112]. Hydroxylation generally takes place at 
the γ-C atom, yielding 4-hydroxyproline (4-Hyp), which has 
the ability to stabilize the secondary structure of the protein 
by the powerful electronegative effect of the hydroxy group 
[112]. Hyp is also associated with the decreased availability 
of oxygen in the cellular environment, as the alpha subunits 
of hypoxia-induced factor (HIF) contain hydroxylated pro-
line residues [113].
Mass spectrometric investigation of collagenous pro-
teins is intricate due to the large number of proline resi-
dues and the high abundance of hydroxylation. These 
structural features result in a vast number of isobaric 
but differently modified peptides in a typical proteomic 
workflow, which usually co-elute during chromatographic 
separation and provide chimeric spectra troublesome to 
elucidate. Moreover, the nominal mass of Hyp is 113 Da, 
which is the same as leucine and isoleucine. To overcome 
such difficulties, a mass spectrometer with high mass 
accuracy and abundant product ions from the tandem MS 
experiment are required [114, 115]. Unfortunately,  MSn 
sequence analysis is ruined by the abnormal fragmenta-
tion of Pro- and Hyp-rich proteins and peptides. These 
residues promote characteristic and dominant cleavages 
instead of those nonselective ones, which may provide 
sequence information. This phenomenon is the so-called 
“proline-effect”, by which the identification of collagens 
and other proline-rich proteins are greatly hampered [114, 
116, 117]. An approach has been suggested that is based 
on the application of five different proteolytic enzymes 
to increase sequence coverage of collagenous proteins. 
Thereafter, the analytes were separated by nano-LC and 
introduced into a linear ion trap–orbitrap instrument. Dif-
ferently modified peptides with the same sequence were 
eluted and ionized together producing chimeric mass spec-
tra. As ETD-induced fragmentation did not yield sufficient 
amount of data, additional dissociation techniques (CID 
and HCD) were also applied. In general, multistage acti-
vation made the identification of PTM-carrying residues 
possible, however, in some cases, the exact localization of 
the modification has remained unknown [114].
Table 2 summarizes the separation/enrichment tech-
niques, fragmentation methods, and commonly used deri-
vatization methods of modified peptides and proteins.
Conclusion and Outlook
Formation of post-translational modifications is the key 
generator of protein diversity. To understand the physi-
ological/pathophysiological processes in our organism and 
be able to produce better quality and more efficient biop-
harmaceutical products and diagnostic procedures, further 
knowledge needs to be gained in the field of proteomics 
and PTM mapping. Mass spectrometry-based proteomic 
approaches has emerged as a powerful device for screening 
and characterizing PTMs. Although the current technology 
is unable to provide a complete picture of the modified 
proteome, future proteomics will rely heavily on contin-
ued improvements of mass spectrometry-based proteomic 
strategies.
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